
Leavenworth’s research could help define the contribution of a subset of immune cells, called follicular regulatory T (TFR) cells to the regulation of tumor immunity and progression.
Insights gained from this project will facilitate the identification of new therapeutic targets and predictive markers of therapeutic outcomes and the development of effective treatment approaches for a broad spectrum of cancers.
Leavenworth’s project began on Dec. 1, 2022, and will continue through Nov. 30, 2027.